Related references
Note: Only part of the references are listed.A systematic review of economic evaluations of treatment regimens in multiple myeloma
Mir Mahmood Asrar et al.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2021)
Cost-Effectiveness of First-Line Versus Second-Line Use of Daratumumab in Older, Transplant-Ineligible Patients With Multiple Myeloma
Kishan K. Patel et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Matthew J. Page et al.
INTERNATIONAL JOURNAL OF SURGERY (2021)
Randomized Clinical Trial Representativeness and Outcomes in Real-World Patients: Comparison of 6 Hallmark Randomized Clinical Trials of Relapsed/Refractory Multiple Myeloma
Ajai Chari et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2020)
Economic Evaluation of Adding Daratumumab to a Regimen of Bortezomib plus Dexamethasone in Relapsed or Refractory Multiple Myeloma: Based on the Latest Updated Analysis of CASTOR
Xiaohui Zeng et al.
CLINICAL THERAPEUTICS (2020)
Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study
Nizar J. Bahlis et al.
LEUKEMIA (2020)
Expanded Access as a source of real-world data: An overview of FDA and EMA approvals
Tobias B. Polak et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2020)
The cost of cancer in Europe 2018
Thomas Hofmarcher et al.
EUROPEAN JOURNAL OF CANCER (2020)
Cost-effectiveness of once weekly carfilzomib 70 mg/m2 plus dexamethasone in patients with relapsed and refractory multiple myeloma in the United States
Shaji K. Kumar et al.
EXPERT REVIEW OF HEMATOLOGY (2020)
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study
Meletios Dimopoulos et al.
LANCET (2020)
Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data
M. Campioni et al.
EUROPEAN JOURNAL OF HEALTH ECONOMICS (2020)
Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups
Robert Z. Orlowski et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2019)
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
T. Facon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Cost-effectiveness analysis on binary/triple therapy on the basis of ixazomib or bortezomib for refractory or relapsed multiple myeloma
Hongfu Cai et al.
LEUKEMIA & LYMPHOMA (2019)
Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review (vol 37, pg 777, 2019)
Dongzhe Hong et al.
PHARMACOECONOMICS (2019)
Cost Effectiveness of Transplant, Conventional Chemotherapy, and Novel Agents in Multiple Myeloma: A Systematic Review
Shuangshuang Fu et al.
PHARMACOECONOMICS (2019)
Daratumumab vs pomalidomide for the treatment of relapsed/refractory multiple myeloma: A cost-effectiveness analysis
Cynthia L. Gong et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Cost-effectiveness of Daratumumab-based Triplet Therapies in Patients With Relapsed or Refractory Multiple Myeloma
Tian-tian Zhang et al.
CLINICAL THERAPEUTICS (2018)
Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study
Sigrun Thorsteinsdottir et al.
HAEMATOLOGICA (2018)
Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (ARROW): interim analysis results of a randomised, phase 3 study
Philippe Moreau et al.
LANCET ONCOLOGY (2018)
Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study
Sigrun Thorsteinsdottir et al.
HAEMATOLOGICA (2018)
Cost-effectiveness of Drugs to Treat Relapsed/Refractory Multiple Myeloma in the United States
Josh J. Carlson et al.
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY (2018)
Evaluating Oncology Value-Based Frameworks in the US Marketplace and Challenges in Real-World Application: A Multiple Myeloma Test Case
Laurence M. Djatche et al.
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY (2018)
Elotuzumab Plus Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Extended 4-Year Follow-Up and Analysis of Relative Progression-Free Survival From the Randomized ELOQUENT-2 Trial
Meletios A. Dimopoulos et al.
CANCER (2018)
Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR
Andrew Spencer et al.
HAEMATOLOGICA (2018)
CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance
Niels W. C. J. van de Donk et al.
FRONTIERS IN IMMUNOLOGY (2018)
Treatment options for refractory/relapsed multiple myeloma: an updated evidence synthesis by network meta-analysis
Xian-Wu Luo et al.
CANCER MANAGEMENT AND RESEARCH (2018)
Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting
Paul G. Richardson et al.
BLOOD CANCER JOURNAL (2018)
Trends in overall survival and costs of multiple myeloma, 2000-2014
R. Fonseca et al.
LEUKEMIA (2017)
Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study
Jian Hou et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial
Meletios A. Dimopoulos et al.
LANCET ONCOLOGY (2017)
Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States
Andrzej J. Jakubowiak et al.
EXPERT REVIEW OF HEMATOLOGY (2017)
Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed-refractory Multiple Myeloma in the United States
Christopher G. Pelligra et al.
CLINICAL THERAPEUTICS (2017)
Cost effectiveness of pomalidomide in patients with relapsed and refractory multiple myeloma in Sweden
Sixten Borg et al.
ACTA ONCOLOGICA (2016)
Systematic review of the economic evaluations of novel therapeutic agents in multiple myeloma: what is the reporting quality?
P. M. Aguiar et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2016)
Elotuzumab for the treatment of multiple myeloma
Yucai Wang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
Sagar Lonial et al.
LANCET (2016)
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
P. Moreau et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
M. A. Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective
Andrzej J. Jakubowiak et al.
JOURNAL OF MEDICAL ECONOMICS (2016)
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Sagar Lonial et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone
Gareth Morgan et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study
Paul G. Richardson et al.
BLOOD (2014)
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
Jesus F. San-Miguel et al.
LANCET ONCOLOGY (2014)
Updating Cost-Effectiveness - The Curious Resilience of the $50,000-per-QALY Threshold
Peter J. Neumann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Evidence Synthesis for Decision Making 1: Introduction
Sofia Dias et al.
MEDICAL DECISION MAKING (2013)
Consolidated Health Economic Evaluation Reporting Standards (CHEERS)-Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force
Don Husereau et al.
VALUE IN HEALTH (2013)
Aphase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma
David S. Siegel et al.
BLOOD (2012)
Critical review of economic evaluations in multiple myeloma: An overview of the economic evidence and quality of the methodology
Jennifer G. Gaultney et al.
EUROPEAN JOURNAL OF CANCER (2011)
The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation
J. Picot et al.
HEALTH TECHNOLOGY ASSESSMENT (2011)
Economic and clinical impact of multiple myeloma to managed care
Richard Cook
JOURNAL OF MANAGED CARE PHARMACY (2008)
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
Meletios Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America
Donna M. Weber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Share Paper
